antibody-dependent cell-mediated cytotoxicity

(redirected from Antibody-dependent cellular cytotoxicity)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to Antibody-dependent cellular cytotoxicity: antibody-dependent cell-mediated cytotoxicity (ADCC)

antibody-dependent cell-mediated cytotoxicity

[‚ant·i‚bäd·ē di¦pen·dənt ‚sel¦mēd·ē‚ād·əd ‚sī·tō·täk′sis·əd·ē]
(immunology)
An immunologic response in which an immunologic effector cell binds to a target cell coated with antibodies, triggering a series of metabolic events that leads to lysis of the target cell.
References in periodicals archive ?
Peregrine's PS-targeting antibodies have been shown to help clear infectious virus from the bloodstream and to induce antibody-dependent cellular cytotoxicity.
BioWa) announced today that it has entered into a second agreement with MedImmune to provide additional access to BioWa's patented POTELLIGENT(R) Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.
In vitro, IgG1 antibodies elicit antibody-dependent cellular cytotoxicity (ADCC), which can kill cancer cells and may contribute to their overall therapeutic effects.
Anti-PS antibodies have been shown to help clear infectious virus from the bloodstream and to induce antibody-dependent cellular cytotoxicity, an important anti-viral immune response.
BioWa) announced today that it has entered into a research agreement which provides GlaxoSmithkline (GSK) with access to BioWa's patented POTELLIGENT(R) Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.
In these studies, SGN-70 also demonstrated significant antibody-dependent cellular cytotoxicity (ADCC) activity.
announced today that it has entered into a license agreement with Merck KGaA, Darmstadt, Germany, providing the global healthcare and chemicals company with access to BioWa's POTELLIGENT Technology platform for the research, development and commercialization of their antibody therapies with enhanced antibody-dependent cellular cytotoxicity (ADCC).
Seattle Genetics has demonstrated that SGN-70 possesses potent antitumor activity in preclinical models of both hematologic malignancies and carcinomas, including complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity.
MDX-1401 is a second-generation anti-CD30 antibody where fucose (a sugar structure) is absent, thereby increasing the antibody's antibody-dependent cellular cytotoxicity, or ADCC, activity (using the Potelligent(R) Technology of BioWa, Inc.

Full browser ?